Skip to main content
. 2018 Aug 14;8:153. doi: 10.1038/s41398-018-0201-z

Fig. 1. Riluzole treatment rescues cognitive impairment in 5XFAD mice.

Fig. 1

a In Y-Maze, there were no significant differences among groups in the ratio of time spent in familiar and start arms during the acquisition phase (F(2,22) = 2.269, p = 0.1271). b There were significant differences among groups in the ratio of time spent in the novel and familiar arms during the trial phase (F(2,21) = 8.736, p = 0.0017): between wild type (WT) and 5XFAD (p = 0.0012) and between 5XFAD and 5XFAD-Riluzole mice (p = 0.04), with WT and 5XFAD-Riluzole mice spending a significantly higher percentage of time in the novel arm. c There were no significant differences in distance traveled during the trial phase (F(2,21) = 1.673, p = 0.2117). The Y-maze data is presented as mean ± S.E.M., and based on WT, n = 10; 5XFAD, n = 6; and 5XFAD-Riluzole, n = 8 mice. *p < 0.05; **p < 0.01